Adicet Bio Inc Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/11/2026)
| Balance Sheet | Total Assets | 192,355,000.00 | ROE | 82.77 % |
| Balance Sheet | Total Equity | 159,210,000.00 | ROA | -60.72 % |
| Cashflow | Capital Expenditures | -1,738,000.00 | P/FCF | -0.35 |
| Cashflow | Free Cash Flow | -96,984,000.00 | – | – |
| Cashflow | Operating Cash Flow | -95,246,000.00 | P/CF | -0.35 |
| Income | Earnings per Share (diluted) | -3.88 | Div. Yield | – |
| Income | Net Income | -116,803,000.00 | P/E | -0.29 |
| Income | Shares Outstanding | 6,891,300.00 | P/B | 0.21 |
| Income | Total Revenue | 1,000.00 | P/S | 33,698.46 |
Ratios calculated on: 10/14/2026
Company Description
Aceto Corporation (Aceto) is primarily engaged in the sourcing, regulatory support, quality assurance, marketing, sales and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical consuming industries. The Company operates in three segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals. The Company has operations in nine countries; it distributes more than 1,100 chemical compounds used principally as finished products or raw materials. The Company has presence in China, Germany, France, the Netherlands, Singapore, India, Hong Kong, the United Kingdom and the United States, along with warehouses worldwide.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.aceto.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more